GENE ONLINE|News &
Opinion
Blog

R&D
Is Antibiotic Resistance Here to Stay?
2020-04-22
Seattle Genetics Enters Breast Cancer Market with Tukysa
2020-04-21
Novartis Announces Mayzent Data that Shows Extended Benefit in Secondary Progressive MS
2020-04-21
Cancer Drug Resistance: Implications in Cancer Therapy
2020-04-20
The Evolution of Lung Cancer Therapies at a Glance
2020-04-16
Beigene’s Tislelizumab-Chemo Combo Nails Primary Endpoint in Phase 3 Trial
2020-04-16
The Search for Disease-Modifying Osteoarthritis Drugs (DMOADs): The Holy Grail of Osteoarthritis Research
2020-04-12
Regeneron & Sanofi’s Phase 3 Dupixent Data on Children Under Regulatory Review
2020-04-10
R&D
Gilead, Second Genome Partner to Explore Microbial Biomarkers
2020-04-08
Samsung Biologics Inks CDO Contract with PharmAbcine to Develop Novel Drug
2020-04-08
Pfizer’s Dupixent Rival Meets Endpoints in Atopic Dermatitis Trial
2020-04-05
Mochida Pharma, Gene Techno Science Collaborate to Develop Regenerative Medicine for Rare Disease
2020-03-28
R&D
Weekly Cover: Eisai to Launch “NouKNOWTM” in Japan for Regular Self-assessment of Brain Health
2020-03-26
Roche Identifies Biomarker that Determines Patient Response to Immunotherapy
2020-03-15
Roche’s Elecsys GALAD Score that Predicts HCC Occurrence, Bags Breakthrough Designation
2020-03-06
1 28 29 30 31 32 34
LATEST
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02
CellTech Accelerator and Cyto-Facto Inc. Forge Strategic Partnership to Advance CGT Industry Growth
2024-04-29
Kaiser’s Data Breach: 13.4 Million Affected in Healthcare Conglomerates Privacy Crisis
2024-04-26
Mechanisms of Allograft Rejection: Insights from Behind the Scenes
2024-04-25
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
EVENT
Scroll to Top